Healthcare / Medical DevicesLSE
$62.00
+3.00 (+5.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-3.0M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$66M
P/E
62.0x
↑EV/EBITDA
2250.4x
↑ROE
-10.1%
↓Gross Margin
88.0%
↑Debt/Equity
0.51
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+36.4%
FCF CAGR
—
FCF margin
-13.5%
FCF / Net income
4.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $58.4M · net income $-1.8M · FCF $-7.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $58.4M | $58.4M | $43.9M | $33.5M | $23.0M |
| Net Income | $-1.8M | $-1.8M | $-8.2M | $-2.8M | $2.0M |
| EBITDA | $2.6M | $2.6M | $-4.3M | $475614.00 | $3.6M |
| EPS | -0.02 | -0.02 | -0.08 | -0.03 | 0.02 |
| Gross Margin | 88.0% | 88.0% | 85.6% | 88.0% | 90.5% |
| Operating Margin | 2.2% | 2.2% | -12.6% | -0.5% | 13.9% |
| Net Margin | -3.0% | -3.0% | -18.6% | -8.4% | 8.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.51 | 0.51 | -2.09 | 16.33 | 0.18 |
| Current Ratio | 3.11 | 3.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.9M | $-7.9M | $-3.0M | $-1.3M | $1.0M |
| Returns | |||||
| ROE | -10.1% | -10.1% | 138.5% | -368.9% | 133.0% |
| Valuation | |||||
| P/E | 62.00 | 62.00 | — | — | — |
| EV/EBITDA | 2250.38 | 2250.38 | — | — | — |
| P/B | 340.40 | 340.40 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 32.9% | 32.9% | 31.1% | 45.8% | — |
| EPS Growth | 74.0% | 74.0% | -191.9% | -238.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → -0.02
Residual
-31.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.